Sanofi reports tolebrutinib submission accepted for FDA priority review
The U.S. Food and Drug Administration is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing ...
Sanofi gets priority review for its multiple sclerosis treatment by FDA
Sanofi (NASDAQ:SNY) said on Tuesday that the US FDA has granted priority review to the regulatory submission of tolebrutinib ...
Zacks Investment Research on MSN17h
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib
Sanofi SNY announced that the FDA has accepted its regulatory filing seeking approval for its investigational BTK inhibitor ...
Rolls-Royce CEO fired managers and held staff brainstorms as part of a ‘4 pillar’ turnaround plan that led to 500% share price jump
Tufan Erginbilgiç's four pillars involved showing employees the extent of Rolls-Royce's issues, then giving them a say in ...